BOSTON SCIENTIFIC CORPORATION Revenue
BOSTON SCIENTIFIC CORPORATION (BSX) reported Revenue of $5.44 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-03
- BOSTON SCIENTIFIC CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $5.44B, a 7.53% increase year-over-year.
- BOSTON SCIENTIFIC CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $5.20B, a 11.58% increase year-over-year.
- BOSTON SCIENTIFIC CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $5.29B, a 15.90% increase year-over-year.
- BOSTON SCIENTIFIC CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $5.07B, a 20.34% increase year-over-year.
- BOSTON SCIENTIFIC CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2025 was $20.07B, a 19.87% increase from fiscal 2024.
- BOSTON SCIENTIFIC CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2024 was $16.75B, a 17.61% increase from fiscal 2023.
- BOSTON SCIENTIFIC CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2023 was $14.24B, a 12.29% increase from fiscal 2022.
- BOSTON SCIENTIFIC CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2022 was $12.68B, a 6.68% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.44B 10-Q · filed 2026-08-03 | $10.65B 10-Q · filed 2026-08-03 | $15.93B derived: sum of 3 quarters · filed 2026-08-03 | $21.00B derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $5.20B 10-Q · filed 2026-05-01 | $10.49B derived: sum of 2 quarters · filed 2026-05-01 | $15.55B derived: sum of 3 quarters · filed 2026-05-01 | $20.61B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $5.29B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $10.35B derived: sum of 2 quarters · filed 2026-02-17 | $15.41B derived: sum of 3 quarters · filed 2026-08-03 | $20.07B 10-K · filed 2026-02-17 |
| 2025-09-30 | $5.07B 10-Q · filed 2025-11-03 | $10.13B derived: sum of 2 quarters · filed 2026-08-03 | $14.79B 10-Q · filed 2025-11-03 | $19.35B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $5.06B 10-Q · filed 2026-08-03 | $9.72B 10-Q · filed 2026-08-03 | $14.29B derived: sum of 3 quarters · filed 2026-08-03 | $18.49B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $4.66B 10-Q · filed 2026-05-01 | $9.22B derived: sum of 2 quarters · filed 2026-05-01 | $13.43B derived: sum of 3 quarters · filed 2026-05-01 | $17.55B derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $4.56B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $8.77B derived: sum of 2 quarters · filed 2026-02-17 | $12.89B derived: sum of 3 quarters · filed 2026-02-17 | $16.75B 10-K · filed 2026-02-17 |
| 2024-09-30 | $4.21B 10-Q · filed 2025-11-03 | $8.33B derived: sum of 2 quarters · filed 2025-11-03 | $12.19B 10-Q · filed 2025-11-03 | $15.91B derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $4.12B 10-Q · filed 2025-08-01 | $7.98B 10-Q · filed 2025-08-01 | $11.70B derived: sum of 3 quarters · filed 2026-02-17 | $15.23B derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $3.86B 10-Q · filed 2025-05-01 | $7.58B derived: sum of 2 quarters · filed 2026-02-17 | $11.11B derived: sum of 3 quarters · filed 2026-02-17 | $14.71B derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $3.73B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $7.25B derived: sum of 2 quarters · filed 2026-02-17 | $10.85B derived: sum of 3 quarters · filed 2026-02-17 | $14.24B 10-K · filed 2026-02-17 |
| 2023-09-30 | $3.53B 10-Q · filed 2024-11-01 | $7.13B derived: sum of 2 quarters · filed 2024-11-01 | $10.52B 10-Q · filed 2024-11-01 | $13.76B derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $3.60B 10-Q · filed 2024-08-01 | $6.99B 10-Q · filed 2024-08-01 | $10.23B derived: sum of 3 quarters · filed 2025-02-18 | $13.40B derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $3.39B 10-Q · filed 2024-05-01 | $6.63B derived: sum of 2 quarters · filed 2025-02-18 | $9.80B derived: sum of 3 quarters · filed 2025-02-18 | $13.04B derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $3.24B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $6.41B derived: sum of 2 quarters · filed 2025-02-18 | $9.66B derived: sum of 3 quarters · filed 2025-02-18 | $12.68B 10-K · filed 2025-02-18 |
| 2022-09-30 | $3.17B 10-Q · filed 2023-11-01 | $6.41B derived: sum of 2 quarters · filed 2023-11-01 | $9.44B 10-Q · filed 2023-11-01 | $12.57B derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $3.24B 10-Q · filed 2023-08-03 | $6.27B 10-Q · filed 2023-08-03 | $9.40B derived: sum of 3 quarters · filed 2024-02-20 | $12.33B derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $3.03B 10-Q · filed 2023-05-04 | $6.15B derived: sum of 2 quarters · filed 2024-02-20 | $9.09B derived: sum of 3 quarters · filed 2024-02-20 | $12.16B derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $3.13B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $6.06B derived: sum of 2 quarters · filed 2024-02-20 | $9.14B derived: sum of 3 quarters · filed 2024-02-20 | $11.89B 10-K · filed 2024-02-20 |
| 2021-09-30 | $2.93B 10-Q · filed 2022-11-03 | $6.01B derived: sum of 2 quarters · filed 2022-11-03 | $8.76B 10-Q · filed 2022-11-03 | $11.47B derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $3.08B 10-Q · filed 2022-08-04 | $5.83B 10-Q · filed 2022-08-04 | $8.54B derived: sum of 3 quarters · filed 2023-02-23 | $11.20B derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $2.75B 10-Q · filed 2022-05-05 | $5.46B derived: sum of 2 quarters · filed 2023-02-23 | $8.12B derived: sum of 3 quarters · filed 2023-02-23 | $10.12B derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $2.71B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $5.37B derived: sum of 2 quarters · filed 2023-02-23 | $7.37B derived: sum of 3 quarters · filed 2023-02-23 | $9.91B 10-K · filed 2023-02-23 |
| 2020-09-30 | $2.66B 10-Q · filed 2021-11-04 | $4.66B derived: sum of 2 quarters · filed 2021-11-04 | $7.20B 10-Q · filed 2021-11-04 | $10.11B derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | $2.00B 10-Q · filed 2021-08-06 | $4.55B 10-Q · filed 2021-08-06 | $7.45B derived: sum of 3 quarters · filed 2022-02-23 | $10.16B derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-03-31 | $2.54B 10-Q · filed 2021-05-06 | $5.45B derived: sum of 2 quarters · filed 2022-02-23 | $8.15B derived: sum of 3 quarters · filed 2022-02-23 | $10.79B derived: sum of 4 quarters · filed 2022-02-23 |
| 2019-12-31 | $2.90B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $5.61B derived: sum of 2 quarters · filed 2022-02-23 | $8.24B derived: sum of 3 quarters · filed 2022-02-23 | $10.73B 10-K · filed 2022-02-23 |
| 2019-09-30 | $2.71B 10-Q · filed 2020-11-05 | $5.34B derived: sum of 2 quarters · filed 2020-11-05 | $7.83B 10-Q · filed 2020-11-05 | $10.39B derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-06-30 | $2.63B 10-Q · filed 2020-08-05 | $5.12B 10-Q · filed 2020-08-05 | $7.68B derived: sum of 3 quarters · filed 2021-02-23 | $10.08B derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-03-31 | $2.49B 10-Q · filed 2020-05-06 | $5.05B derived: sum of 2 quarters · filed 2021-02-23 | $7.45B derived: sum of 3 quarters · filed 2021-02-23 | $9.94B derived: sum of 4 quarters · filed 2021-02-23 |
| 2018-12-31 | $2.56B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $4.95B derived: sum of 2 quarters · filed 2021-02-23 | $7.44B derived: sum of 3 quarters · filed 2021-02-23 | $9.82B 10-K · filed 2021-02-23 |
| 2018-09-30 | $2.39B 10-Q · filed 2019-11-05 | $4.88B derived: sum of 2 quarters · filed 2019-11-05 | $7.26B 10-Q · filed 2019-11-05 | $9.67B derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $2.49B 10-Q · filed 2019-07-30 | $4.87B 10-Q · filed 2019-07-30 | $7.28B derived: sum of 3 quarters · filed 2020-02-25 | $9.50B derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $2.38B 10-Q · filed 2019-04-29 | $4.79B derived: sum of 2 quarters · filed 2020-02-25 | $7.01B derived: sum of 3 quarters · filed 2020-02-25 | $9.27B derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $2.41B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $4.63B derived: sum of 2 quarters · filed 2020-02-25 | $6.89B derived: sum of 3 quarters · filed 2020-02-25 | $9.05B 10-K · filed 2020-02-25 |
| 2017-09-30 | $2.22B 10-Q · filed 2018-10-29 | $4.48B derived: sum of 2 quarters · filed 2018-10-29 | $6.64B 10-Q · filed 2018-10-29 | |
| 2017-06-30 | $2.26B 10-Q · filed 2018-07-31 | $4.42B 10-Q · filed 2018-07-31 | ||
| 2016-12-31 | $8.39B 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| 3M CO (MMM) | United States | $86.404B | 27.87 |
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| STRYKER CORP (SYK) | United States | $103.511B | 32.39 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |